Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ALMS Alumis Inc.

未开盘 09-15 16:00:00 EDT

8.40

-0.82

-8.89%

盘后8.45

+0.05+0.56%

19:47 EDT

最高9.20	最低8.31	成交量400.46万
今开9.18	昨收9.22	日振幅9.65%
总市值10.84亿	流通市值8.16亿	总股本1.29亿
成交额3,393万	换手率4.12%	流通股本9,715万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":8.4,"timestamp":1789502400000,"preClose":9.22,"halted":0,"volume":4004618,"hourTrading":{"tag":"盘后","latestPrice":8.4469,"preClose":8.4,"latestTime":"19:47 EDT","volume":94998,"amount":798065.2317,"timestamp":1789516058488,"change":0.0469,"changeRate":0.005583,"amplitude":0.008333},"delay":0,"changeRate":-0.0889370932754881,"floatShares":97154700,"shares":129000000,"eps":-3.800544,"marketStatus":"未开盘","change":-0.82,"latestTime":"09-15 16:00:00 EDT","open":9.18,"high":9.2,"low":8.31,"amount":33934936.705717996,"amplitude":0.096529,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":9.22,"preHourTrading":{"tag":"盘前","latestPrice":9.1181,"preClose":9.22,"latestTime":"09:01 EDT","volume":3103,"amount":28042.350922,"timestamp":1789477286823,"change":-0.1019,"changeRate":-0.011052,"amplitude":0.032115},"postHourTrading":{"tag":"盘后","latestPrice":8.4469,"preClose":8.4,"latestTime":"19:47 EDT","volume":94998,"amount":798065.2317,"timestamp":1789516058488,"change":0.0469,"changeRate":0.005583,"amplitude":0.008333},"volumeRatio":0.973673,"impliedVol":0.815,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/ALMS/tweets","defaultTab":"tweets","newsList":[{"id":"1102339511","title":"Alumis公布Envudeucitinib治疗系统性红斑狼疮（SLE）2B期临床试验的初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1102339511","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102339511?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262275,"startTime":"0","endTime":"0","summary":"Alumis公司今日对外宣布，其针对Envudeucitinib在系统性红斑狼疮适应症上开展的2B期临床试验，现已获得初步顶线数据。SLE作为一种复杂的自身免疫性疾病，长期以来缺乏高效且安全的治疗选择，而这一最新进展无疑为领域内带来了新的期待。该研究旨在评估Envudeucitinib在不同剂量方案下，对于中重度活动性SLE患者的疗效与安全性。这一里程碑式的进展，不仅可能重塑SLE的治疗格局，也为广大患者带来了潜在的创新疗法希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124847402","title":"Alumis：干扰素基因高表达亚组响应强劲，为Envudeucitinib在系统性红斑狼疮中的三期临床开发提供有力支撑","url":"https://stock-news.laohu8.com/highlight/detail?id=1124847402","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124847402?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:31","pubTimestamp":1788262274,"startTime":"0","endTime":"0","summary":"Alumis公司公布的最新数据表明，在干扰素基因特征高表达的亚组患者中，Envudeucitinib展现出了强劲且稳健的治疗响应。这一积极结果，无疑为该公司正在推进的、针对系统性红斑狼疮的Envudeucitinib三期临床开发计划，注入了强有力的信心与数据支撑。基于此，Alumis公司正加速推进Envudeucitinib的后期临床研究，旨在为这一长期缺乏新疗法的疾病领域带来创新选择。此次数据的发布，或将为Envudeucitinib后续的临床路径及监管沟通奠定更为有利的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138091701","title":"Alumis旗下Envudeucitinib在两项三期试验中展现皮肤清除、生活质量及银屑病症状早期显著改善，凸显其作为斑块状银屑病一线口服疗法的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1138091701","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138091701?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:31","pubTimestamp":1774719072,"startTime":"0","endTime":"0","summary":"Alumis公司研发的Envudeucitinib在两项三期临床试验中取得突破性进展，该口服疗法在皮肤清除率、患者生活质量和银屑病核心症状方面均表现出早期且显著的改善效果。试验数据进一步验证了其作为斑块状银屑病前沿口服治疗方案的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199051063","title":"Alumis持续推进Envudeucitinib长期疗效与安全性评估：Onward3长期扩展试验进行中","url":"https://stock-news.laohu8.com/highlight/detail?id=1199051063","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199051063?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719029,"startTime":"0","endTime":"0","summary":"Alumis Inc. 目前正通过Onward3长期扩展试验，持续评估其在研药物Envudeucitinib的长期疗效与安全性表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197813725","title":"Alumis：Envudeucitinib展现强劲皮肤清除效果，两项试验中从第16周至第24周均实现高阈值临床应答","url":"https://stock-news.laohu8.com/highlight/detail?id=1197813725","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197813725?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719011,"startTime":"0","endTime":"0","summary":"Alumis公司宣布，其研究药物Envudeucitinib在两项临床试验中表现出强大的皮肤清除能力。从治疗的第16周开始，直至第24周，该药物持续达到了高标准的临床应答阈值，显示出显著且持久的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144581026","title":"Alumis公布Envudeucitinib安全性数据：与二期项目一致，未出现新的安全信号","url":"https://stock-news.laohu8.com/highlight/detail?id=1144581026","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144581026?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:30","pubTimestamp":1774719010,"startTime":"0","endTime":"0","summary":"Alumis Inc. 近日披露了Envudeucitinib的最新临床数据，显示该药物在安全性与耐受性方面表现良好，结果与二期临床试验项目的数据保持一致。研究中未观察到新的安全性信号，进一步支持了该疗法的开发前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104384434","title":"Alumis公布Envudeucitinib治疗中重度斑块型银屑病三期数据，将于2026年AAD年会作重磅报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1104384434","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104384434?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:04","pubTimestamp":1773835493,"startTime":"0","endTime":"0","summary":"生物制药公司Alumis Inc.宣布，其主打候选药物Envudeucitinib用于中重度斑块型银屑病治疗的三期临床试验数据，已被遴选为2026年美国皮肤病学会年会的\"迟来突破\"口头报告环节。该环节专门展示具有高度临床价值的最新研究成果，意味着Envudeucitinib的三期数据获得了学术委员会对其科学重要性的认可。若三期数据积极，该药物有望在2026年AAD年会前后提交上市申请，切入规模可观的银屑病治疗市场。Alumis计划在2026年AAD年会上公布Envudeucitinib三期试验的详细疗效与安全性结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518273429","title":"Alumis Inc.盘中异动 大幅跳水5.64%报4.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518273429","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518273429?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:54","pubTimestamp":1741614889,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时54分，Alumis Inc.股票出现波动，股价大幅跳水5.64%。截至发稿，该股报4.61美元/股，成交量1857股，换手率0.00%，振幅1.02%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.21%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215449abf3052c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310215449abf3052c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517916788","title":"Alumis Inc.盘中异动 股价大涨5.08%报4.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517916788","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517916788?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:04","pubTimestamp":1741277052,"startTime":"0","endTime":"0","summary":"北京时间2025年03月07日00时04分，Alumis Inc.股票出现波动，股价快速拉升5.08%。截至发稿，该股报4.96美元/股，成交量1.918万股，换手率0.04%，振幅5.93%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.38%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412abeb8dec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000412abeb8dec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320167","title":"Alumis Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320167","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320167?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:41","pubTimestamp":1740753709,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时41分，Alumis Inc.股票出现异动，股价大幅下挫5.03%。截至发稿，该股报4.44美元/股，成交量8467股，换手率0.02%，振幅7.03%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822414996341c29&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822414996341c29&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514423389","title":"Alumis Inc.盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514423389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514423389?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:06","pubTimestamp":1740668794,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时06分，Alumis Inc.股票出现波动，股价急速上涨5.03%。截至发稿，该股报4.80美元/股，成交量1.9713万股，换手率0.04%，振幅3.72%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.79%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272306359632b8dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272306359632b8dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514862256","title":"Alumis Inc.盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514862256","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514862256?lang=zh_cn&edition=full","pubTime":"2025-02-27 04:26","pubTimestamp":1740601598,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日04时26分，Alumis Inc.股票出现波动，股价急速跳水5.15%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.66%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Geovax Labs Inc C/Wts 29/09/2025涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6840.61%、330.94%、264.62%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为194.07%、81.11%、70.39%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042639abde3a22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227042639abde3a22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514429018","title":"Alumis Inc.盘中异动 股价大跌5.34%报4.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514429018","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514429018?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:57","pubTimestamp":1740495429,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时57分，Alumis Inc.股票出现波动，股价急速下挫5.34%。截至发稿，该股报4.96美元/股，成交量2.8417万股，换手率0.05%，振幅7.35%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225709abdc845b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225709abdc845b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513177839","title":"Alumis Inc.盘中异动 早盘急速上涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513177839","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513177839?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:53","pubTimestamp":1740408789,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时53分，Alumis Inc.股票出现波动，股价大幅上涨5.19%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.22%。其相关个股中，Pepgen Inc.、Telix Pharmaceutic、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为133.79%、54.99%、25.03%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225309abdb1332&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224225309abdb1332&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513163291","title":"Alumis Inc.盘中异动 早盘急速拉升5.17%报5.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513163291","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513163291?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:12","pubTimestamp":1740150764,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时12分，Alumis Inc.股票出现异动，股价快速上涨5.17%。截至发稿，该股报5.40美元/股，成交量6.9518万股，换手率0.13%，振幅5.36%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为0.13%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231244988de812&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231244988de812&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510261353","title":"Alumis Inc.盘中异动 下午盘快速拉升5.19%报5.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510261353","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510261353?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:30","pubTimestamp":1739298654,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时30分，Alumis Inc.股票出现波动，股价大幅上涨5.19%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为1.79%。其相关个股中，Omega Therapeutics, Inc.、Dominari Holdings Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3088.31%、1431.52%、482.49%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、72.23%、58.60%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120230549881e514&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120230549881e514&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510861395","title":"Alumis Inc.盘中异动 早盘股价大跌5.29%报5.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510861395","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510861395?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:25","pubTimestamp":1739201112,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时25分，Alumis Inc.股票出现异动，股价急速下挫5.29%。截至发稿，该股报5.37美元/股，成交量4.4468万股，换手率0.08%，振幅6.35%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.23%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210232512988083b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210232512988083b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509374465","title":"Alumis Inc.股价重挫19.58% 市值跌5646.07万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509374465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509374465?lang=zh_cn&edition=full","pubTime":"2025-02-07 22:31","pubTimestamp":1738938684,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日22时31分，Alumis Inc.股票出现波动，股价快速下跌19.58%。截至发稿，该股报5.30美元/股，成交量2.4305万股，换手率0.04%，振幅2.12%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223125abc62ab0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207223125abc62ab0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509200216","title":"Alumis Inc.盘中异动 快速跳水5.19%报6.76美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509200216","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509200216?lang=zh_cn&edition=full","pubTime":"2025-02-07 02:47","pubTimestamp":1738867675,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日02时47分，Alumis Inc.股票出现波动，股价快速跳水5.19%。截至发稿，该股报6.76美元/股，成交量5.3462万股，换手率0.10%，振幅6.17%。Alumis Inc.股票所在的生物技术行业中，整体跌幅为0.31%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207024755987cb35c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207024755987cb35c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507618399","title":"Alumis Inc.盘中异动 大幅上涨5.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507618399","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507618399?lang=zh_cn&edition=full","pubTime":"2025-01-31 23:10","pubTimestamp":1738336244,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日23时10分，Alumis Inc.股票出现波动，股价快速上涨5.65%。Alumis Inc.股票所在的生物技术行业中，整体涨幅为1.19%。其相关个股中，Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.涨幅较大，Nls Pharmaceutics Ltd.、Cyclerion Therapeutics, Inc.、Silexion Therapeutics Corp较为活跃，换手率分别为1748.29%、1467.52%、110.55%，振幅较大的相关个股有Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为63.20%、56.30%、46.27%。Alumis Inc.公司简介：Alumis Inc 是一家临床阶段的生物制药公司，专注于识别、收购和加速自身免疫性疾病变革性药物的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131231044a235497d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131231044a235497d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":-0.206},{"period":"1month","weight":-0.6681},{"period":"3month","weight":-0.6356},{"period":"6month","weight":-0.669},{"period":"1year","weight":0.9178},{"period":"ytd","weight":-0.1393}],"compareEarnings":[{"period":"1week","weight":-0.0112},{"period":"1month","weight":-0.0244},{"period":"3month","weight":0.0222},{"period":"6month","weight":0.1479},{"period":"1year","weight":0.146},{"period":"ytd","weight":0.1107}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Alumis Inc.于2021年1月29日注册成立，为特拉华州公司。他们是一家临床阶段的生物制药公司，最初专注于开发两种酪氨酸激酶2（TYK2）抑制剂：ESK-001，一种他们正在开发的第二代抑制剂，以实现最大的靶向抑制，以及A-005，一种中枢神经系统渗透分子。该公司的使命是通过靶向治疗取代广泛的免疫抑制，显著改善患者的生活。","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Alumis Inc.(ALMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}